Vistagen Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vistagen Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.16M, a 104% increase year-over-year.
  • Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $2.77M, a 5.97% decline year-over-year.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.18M, a 34.6% decline from 2022.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.34M, a 4.13% decline from 2021.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $3.48M, a 50.9% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $2.18M -$1.16M -34.6% Apr 1, 2023 Mar 31, 2024 10-K 2024-06-11
2022 $3.34M -$144K -4.13% Apr 1, 2022 Mar 31, 2023 10-K 2024-06-11
2021 $3.48M +$1.17M +50.9% Apr 1, 2021 Mar 31, 2022 10-K 2023-06-28
2020 $2.31M -$1.51M -39.6% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-23
2019 $3.82M +$377K +11% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-29
2018 $3.44M +$1.1M +46.9% Apr 1, 2018 Mar 31, 2019 10-K 2020-06-30
2017 $2.34M +$1.49M +175% Apr 1, 2017 Mar 31, 2018 10-K 2019-06-25
2016 $851K -$3.19M -78.9% Apr 1, 2016 Mar 31, 2017 10-K 2018-06-26
2015 $4.04M +$1.58M +64.3% Apr 1, 2015 Mar 31, 2016 10-K 2017-06-29
2014 $2.46M Apr 1, 2014 Mar 31, 2015 10-K 2016-06-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.